Restart Life Sciences Corp.
HEAL.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.74M
Close$
$0.04
46.8% downside
Current Fair Value
46.8% downsideOvervalued by 46.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.74 Million |
|---|---|
| Enterprise Value | $2.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | -0.78 |
| Outstanding Shares | 60,748,513 |
Return
| Return on Equity | -0.93% |
|---|---|
| Return on Assets | -0.90% |
| Return on Invested Capital | -6.29% |
Valuation & Multiples
| P/E Ratio | -1.83 |
|---|---|
| PEG | 1.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.83 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Restart Life Sciences Corp.
3 employees
CEO: Steve Loutskou Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spect...